Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
Abivax (Euronext: ABVX, Nasdaq: ABVX) has appointed Dr. Dominik Höchli to its Board of Directors, effective immediately. Dr. Höchli brings over 20 years of leadership experience in global biopharma, including a significant tenure at AbbVie/Abbott as Vice President of Global Marketing for Immunology and Head of Global Medical Affairs.
The appointment comes at a important time as Abivax approaches its Phase 3 data readout for the 8-week induction trial in ulcerative colitis, expected in Q3 2025. Dr. Höchli's expertise in medical strategy and commercialization within immunology markets will be valuable for the company's development of obefazimod for ulcerative colitis and Crohn's disease.
Dr. Höchli previously served as Interim CEO of Catapult Therapeutics (2021-2024) and currently serves on the Board of Directors at Molecular Partners AG. He is also the founder of Abinode, a pharmaceutical strategy consulting firm.
Abivax (Euronext: ABVX, Nasdaq: ABVX) ha nominato con effetto immediato Dr. Dominik Höchli nel suo Consiglio di Amministrazione. Il Dr. Höchli vanta oltre 20 anni di esperienza dirigenziale nel settore biofarmaceutico globale, inclusa una lunga esperienza in AbbVie/Abbott come Vicepresidente del Marketing Globale per Immunologia e Responsabile delle Relazioni Mediche Globali.
La nomina arriva in un momento cruciale, mentre Abivax si avvicina alla pubblicazione dei dati di Fase 3 del trial di induzione di 8 settimane per la colite ulcerosa, prevista per il terzo trimestre 2025. L’esperienza del Dr. Höchli nella strategia medica e nella commercializzazione nei mercati dell’immunologia sarà preziosa per lo sviluppo di obefazimod per la colite ulcerosa e la malattia di Crohn.
Il Dr. Höchli è stato precedentemente Amministratore Delegato ad interim di Catapult Therapeutics (2021-2024) e attualmente è membro del Consiglio di Amministrazione di Molecular Partners AG. È anche fondatore di Abinode, una società di consulenza strategica farmaceutica.
Abivax (Euronext: ABVX, Nasdaq: ABVX) ha nombrado con efecto inmediato a Dr. Dominik Höchli en su Junta Directiva. El Dr. Höchli aporta más de 20 años de experiencia en liderazgo en biofarmacéutica global, incluyendo un periodo significativo en AbbVie/Abbott como Vicepresidente de Marketing Global para Inmunología y Jefe de Asuntos Médicos Globales.
El nombramiento llega en un momento importante, ya que Abivax se acerca a la publicación de datos de Fase 3 del ensayo de inducción de 8 semanas para colitis ulcerosa, previsto para el tercer trimestre de 2025. La experiencia del Dr. Höchli en estrategia médica y comercialización en mercados de inmunología será valiosa para el desarrollo de obefazimod para colitis ulcerosa y enfermedad de Crohn.
El Dr. Höchli fue anteriormente CEO interino de Catapult Therapeutics (2021-2024) y actualmente forma parte del Consejo de Administración de Molecular Partners AG. También es fundador de Abinode, una consultora de estrategia farmacéutica.
Abivax(유로넥스트: ABVX, 나스닥: ABVX)는 즉시 발효되는 이사회 멤버로 도미닉 회흘리 박사를 임명했습니다. 회흘리 박사는 글로벌 바이오제약 분야에서 20년 이상의 리더십 경험을 보유하고 있으며, AbbVie/Abbott에서 면역학 글로벌 마케팅 부사장 및 글로벌 의료 담당 책임자로 근무한 경력이 있습니다.
이번 임명은 Abivax가 2025년 3분기에 예정된 궤양성 대장염 8주 유도 임상 3상 데이터 공개를 앞두고 중요한 시기에 이루어졌습니다. 회흘리 박사의 면역학 시장 내 의료 전략 및 상업화 전문성은 궤양성 대장염과 크론병 치료제인 오베파지모드 개발에 큰 도움이 될 것입니다.
회흘리 박사는 이전에 Catapult Therapeutics의 임시 CEO(2021-2024)를 역임했으며, 현재 Molecular Partners AG 이사회 멤버로 활동 중입니다. 또한 제약 전략 컨설팅 회사인 Abinode의 창립자이기도 합니다.
Abivax (Euronext : ABVX, Nasdaq : ABVX) a nommé avec effet immédiat Dr. Dominik Höchli au sein de son Conseil d’Administration. Le Dr Höchli apporte plus de 20 ans d’expérience en leadership dans la biopharmacie mondiale, notamment un long passage chez AbbVie/Abbott en tant que Vice-Président du Marketing Global pour l’Immunologie et Responsable des Affaires Médicales Globales.
Cette nomination intervient à un moment clé, alors qu’Abivax s’apprête à publier les résultats de la Phase 3 de l’essai d’induction de 8 semaines dans la colite ulcéreuse, attendus au troisième trimestre 2025. L’expertise du Dr Höchli en stratégie médicale et commercialisation dans les marchés de l’immunologie sera précieuse pour le développement d’obefazimod dans la colite ulcéreuse et la maladie de Crohn.
Le Dr Höchli a précédemment été CEO par intérim de Catapult Therapeutics (2021-2024) et siège actuellement au Conseil d’Administration de Molecular Partners AG. Il est également le fondateur d’Abinode, une société de conseil en stratégie pharmaceutique.
Abivax (Euronext: ABVX, Nasdaq: ABVX) hat mit sofortiger Wirkung Dr. Dominik Höchli in seinen Vorstand berufen. Dr. Höchli bringt über 20 Jahre Führungserfahrung in der globalen Biopharma-Branche mit, darunter eine bedeutende Zeit bei AbbVie/Abbott als Vice President Global Marketing für Immunologie und Leiter der Global Medical Affairs.
Die Ernennung erfolgt zu einem wichtigen Zeitpunkt, da Abivax auf die Phase-3-Datenauswertung der 8-wöchigen Induktionsstudie bei Colitis ulcerosa im dritten Quartal 2025 zusteuert. Dr. Höchlis Expertise in medizinischer Strategie und Kommerzialisierung im Immunologiemarkt wird für die Weiterentwicklung von Obefazimod bei Colitis ulcerosa und Morbus Crohn wertvoll sein.
Dr. Höchli war zuvor Interims-CEO von Catapult Therapeutics (2021-2024) und ist derzeit Mitglied des Vorstands von Molecular Partners AG. Zudem ist er Gründer von Abinode, einer Beratungsgesellschaft für pharmazeutische Strategien.
- Strategic board appointment brings valuable immunology expertise ahead of important Phase 3 readout
- New director brings 20+ years of relevant leadership experience from AbbVie/Abbott
- Strengthens company's commercial preparation capabilities in competitive immunology market
- Phase 3 trial results not expected until Q3 2025, indicating significant wait for key clinical milestone
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
- Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025
PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately.
Dr. Höchli brings over two decades of leadership experience in global biopharma, most notably a 20-year tenure at AbbVie/Abbott, where he served as Vice President of Global Marketing for Immunology and later as Head of Global Medical Affairs. His strategic expertise in medical affairs and product positioning—particularly within competitive immunology markets—will be instrumental as Abivax prepares for the upcoming Phase 3 data readout for the 8-week induction trial in ulcerative colitis expected in Q3 2025.
In addition to his experience at AbbVie, Dr. Höchli served as Interim CEO of Catapult Therapeutics, a hematology-oncology company, from 2021 to 2024. He is also the founder of Abinode, a pharmaceutical strategy consulting firm, and currently serves on the Board of Directors at Molecular Partners AG, where he is a member of both the Audit Committee and the Research & Development Committee.
Sylvie Grégoire, Chair of Abivax Board of Directors, commented: “We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical strategy and commercialization within immunology will be invaluable as we approach key clinical and regulatory inflection points for obefazimod.”
Dr. Dominik Höchli added: “I’m excited to join the Board at a time when Abivax is entering a critical phase of clinical development and to support the company’s efforts to bring obefazimod to patients living with ulcerative colitis and Crohn’s disease."
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow Abivax on LinkedIn and on X, formerly Twitter, Abivax.
Contact:
Patrick Malloy
SVP, Investor Relations, Abivax
patrick.malloy@abivax.com
+1 847 987 4878
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business objectives. Words such as “anticipate,” “continue,” “expect,” “forward,” “potential” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning or implying the therapeutic potential of Abivax's drug candidates, Abivax’s expectations regarding the availability of data and timing of reporting results from its clinical trials, including its Phase 3 ABTECT-1 and ABTECT-2 induction trials and Phase 3 ABTECT maintenance trial, and other statements that are not historical fact. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe for, securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.
FAQ
When is Abivax (ABVX) expecting Phase 3 trial results for ulcerative colitis treatment?
What is Dr. Dominik Höchli's experience before joining Abivax's (ABVX) Board?
What therapeutic areas is Abivax (ABVX) currently focusing on?
What is the significance of Dr. Höchli's appointment to Abivax (ABVX)?
